TABLE 1.
Overview of clinically relevant DPYD variants
| rs number | DPYD variant | Nucleotide change | Dose recommendation |
|---|---|---|---|
| rs3918290 | DPYD *2A | c.1905 + 1G > A/IVS14 + 1G > A |
50% dose reduction of 5‐FU based treatment a A gradual dose escalation is recommended in patients tolerating the 50% dose well. |
| rs67376798 | D949V | c.2846A > T | |
| rs55886062 | DPYD*13 | c.1679 T > G | |
| rs56038477 or rs75018182 | “HapB3” | c.1236G > A | |
| c.1129‐5923C > G | |||
| c.483 + 18G > A |
a
Patients heterozygous for one of the listed DPYD‐variants. [Correction added on 26 September 2022, after first online publication: Minor formatting/typographical changes have been made to Table 1.]